NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Structured Abstract
Background:
Medications to reduce breast cancer risk are an effective prevention intervention for women at increased risk, although medications also cause adverse effects.
Purpose:
To update the 2013 U.S. Preventive Services Task Force (USPSTF) systematic review on the use of medications to reduce the risk of primary breast cancer.
Data Sources:
Searches included the Cochrane Central Register of Controlled Trials, the Cochrane Database of Systematic Reviews, EMBASE, and MEDLINE (January 1, 2013 to February 1, 2019); and manual review of reference lists. Studies published before 2013 were identified from prior systematic reviews for the USPSTF.
Study Selection:
Discriminatory accuracy studies of breast cancer risk assessment methods; double-blind, placebo-controlled or head-to-head randomized controlled trials (RCT) of tamoxifen, raloxifene, and aromatase inhibitors for primary prevention of breast cancer that enrolled women without preexisting breast cancer; and RCTs and observational studies of harms of medications.
Data Extraction:
One investigator abstracted data on study methods; setting; population characteristics; eligibility criteria; interventions; numbers enrolled and lost to followup; method of outcome ascertainment; and results for each outcome and a second investigator checked abstractions for accuracy. Two investigators independently assessed study quality using methods developed by the USPSTF.
Data Synthesis (Results):
Eighteen risk models evaluated in 25 studies had generally low discriminatory accuracy in predicting the probability of breast cancer in an individual (c-statistics 0.55 to 0.65). Most models performed only slightly better than age alone as a risk predictor. No studies evaluated optimal ages or frequencies of risk assessment.
In placebo-controlled trials, tamoxifen (risk ratio [RR] 0.69; 95% confidence interval [CI], 0.59 to 0.84; 7 fewer cases per 1000 women over 5 years of use [95% CI, 4 to 12]; 4 trials), raloxifene (RR 0.44; 95% CI, 0.24 to 0.80; 9 fewer cases [95% CI, 3 to 15]; 2 trials), and the aromatase inhibitors exemestane and anastrozole (RR 0.45; 95% CI, 0.26 to 0.70; 16 fewer cases [95% CI, 8 to 24]; 2 trials) reduced invasive breast cancer. Risk for invasive breast cancer was higher for raloxifene than tamoxifen in the Study of Tamoxifen And Raloxifene (STAR) head-to-head trial (RR, 1.24; 95% CI, 1.05 to 1.47) after long-term followup. Effects did not differ by age of initiation or duration of use (3 to 5 years), although these effects were not directly compared. Risk reduction persisted at least 8 years after discontinuation in tamoxifen trials with long-term followup. All medications reduced estrogen receptor positive, but not estrogen receptor negative invasive breast cancer; tamoxifen reduced noninvasive cancer in two trials; and breast-cancer specific and all-cause mortality were not reduced.
In placebo-controlled trials, raloxifene (RR 0.61; 95% CI, 0.53 to 0.73; 2 trials) reduced vertebral fractures; tamoxifen reduced nonvertebral fractures in the National Surgical Adjuvant Breast and Bowel Project (NSABP P-1) trial (RR 0.66; 95% CI, 0.45 to 0.98); while the aromatase inhibitors had no effect on fractures. Tamoxifen and raloxifene had similar effects on reducing fractures at multiple vertebral and nonvertebral sites in the STAR head-to-head trial.
In placebo-controlled trials, tamoxifen (RR 1.93; 95% CI, 1.33 to 2.68; 4 trials) and raloxifene (RR 1.56; 95% CI, 1.11 to 2.60; 2 trials) increased thromboembolic events, while aromatase inhibitors did not. Raloxifene caused fewer thromboembolic events (RR 0.75; 95% CI, 0.60 to 0.93) than tamoxifen in the STAR head-to-head trial. Tamoxifen, raloxifene, and aromatase inhibitors did not increase coronary heart disease events or strokes.
In placebo-controlled trials, tamoxifen increased endometrial cancer (RR 2.25; 95% CI, 1.17 to 4.41; 3 trials), while raloxifene and aromatase inhibitors did not. In the STAR head-to-head trial, raloxifene caused fewer cases of endometrial cancer (RR 0.55; 95% CI, 0.36 to 0.83) and endometrial hyperplasia (RR 0.19; 95% CI, 0.12 to 0.29), and fewer hysterectomies (RR 0.45; 95% CI, 0.37 to 0.54) than tamoxifen. Tamoxifen increased cataracts (RR 1.22; 95% CI, 1.08 to 1.48; 3 trials) and cataract surgery compared with placebo, while raloxifene and aromatase inhibitors did not. Risks for thromboembolic events and endometrial cancer with tamoxifen were higher for older compared with younger women and returned to normal after discontinuation. All medications caused adverse effects, such as vasomotor or musculoskeletal symptoms, that varied by medication.
Risks for invasive cancer were generally reduced in all population subgroups evaluated based on menopausal status (pre and postmenopausal); family history of breast cancer; body mass index categories; modified Gail model risk categories; and age at menarche, parity, or age at first live birth, although results varied. Tamoxifen and anastrozole had larger effects in reducing invasive breast cancer in women with previous breast lesions (lobular carcinoma in situ, atypical ductal hyperplasia, or atypical lobular hyperplasia).
Limitations:
Trials were limited by clinical heterogeneity related to different medications, exposure durations, eligibility criteria, adherence, and ascertainment of outcomes. No trials compared timing and duration directly. Long-term followup data were lacking from most trials, and followup was particularly short for the aromatase inhibitors. Trials were not designed for subgroup comparisons and analysis of differences may be underpowered.
Conclusions:
Tamoxifen, raloxifene, and the aromatase inhibitors exemestane and anastrozole reduce invasive breast cancer in women without preexisting breast cancer, but also cause adverse effects that vary by medication. Tamoxifen and raloxifene increase thromboembolic events and tamoxifen increases endometrial cancer and cataracts. Identifying candidates for therapy is complicated by risk stratification methods that demonstrate low accuracy.
Contents
- Acknowledgments
- Chapter 1. Introduction and Background
- Chapter 2. Methods
- Chapter 3. Results
- Key Question 1. In Adult Women Without Preexisting Breast Cancer, What Is the Accuracy of Risk Assessment Methods to Identify Women Who Could Benefit From Medications to Reduce Risk for Primary Breast Cancer?
- Key Question 1a. What Is the Optimal Age at Which to Begin Risk Assessment to Identify Women Who Could Benefit From Medications to Reduce Risk for Primary Breast Cancer?
- Key Question 1b. What Is the Optimal Frequency of Risk Assessment to Identify Women Who Could Benefit From Medications to Reduce Risk for Primary Breast Cancer?
- Key Question 2. In Adult Women Without Preexisting Breast Cancer, What Is the Effectiveness and Comparative Effectiveness of Medications to Reduce Risk for Primary Breast Cancer on Improvement in Short- and Long-Term Health Outcomes?
- Key Question 2a. Does the Effectiveness of Risk-Reducing Medications Vary by Timing of Initiation or Duration of Use?
- Key Question 2b. Does the Effectiveness of Risk-Reducing Medications Persist Beyond Discontinuation of Use?
- Key Question 3. What Are the Harms of Using Medications to Reduce Risk for Primary Breast Cancer?
- Key Question 3a. Do Harms of Risk-Reducing Medications Vary by Timing of Initiation and/or Duration of Use?
- Key Question 3b. Do Harms of Risk-Reducing Medications Persist Beyond Discontinuation of Use?
- Key Question 4. How Do Outcomes Vary by Population Subgroups?
- Contextual Question 1. What Are Current Clinician and Patient Attitudes and Practices Regarding Use of Medications to Reduce Risk for Primary Breast Cancer? Do They Vary by Population Subgroups?
- Contextual Question 2. How Well Do Statistical Models Inform the Practice of Identifying and Treating Women With Medications to Reduce Risk for Breast Cancer?
- Chapter 4. Discussion
- References
- Appendixes
Suggested citation:
Nelson HD, Fu R, Zakher B, McDonagh M, Pappas M, Stillman L. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 180. AHRQ Publication No. 19-05249-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2019.
This report is based on research conducted by the Pacific Northwest Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (HHSA-290-2015-0000-9I, Task Order No. 7). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.
The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).
This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.
None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.
- NLM CatalogRelated NLM Catalog Entries
- Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.[JAMA. 2019]Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.Nelson HD, Fu R, Zakher B, Pappas M, McDonagh M. JAMA. 2019 Sep 3; 322(9):868-886.
- Risk-reducing medications for primary breast cancer: a network meta-analysis.[Cochrane Database Syst Rev. 2019]Risk-reducing medications for primary breast cancer: a network meta-analysis.Mocellin S, Goodwin A, Pasquali S. Cochrane Database Syst Rev. 2019 Apr 29; 4(4):CD012191. Epub 2019 Apr 29.
- Review Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force[ 2019]Review Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task ForceNelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L. 2019 Aug
- Review Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force[ 2015]Review Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task ForceWhitlock EP, Williams SB, Burda BU, Feightner A, Beil T. 2015 Sep
- Review Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.[Ann Intern Med. 2009]Review Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer.Nelson HD, Fu R, Griffin JC, Nygren P, Smith ME, Humphrey L. Ann Intern Med. 2009 Nov 17; 151(10):703-15, W-226-35.
- Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Syste...Medication Use for the Risk Reduction of Primary Breast Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force
Your browsing activity is empty.
Activity recording is turned off.
See more...